Effects of LDL and oxLDL on expression of PCSK9 and LDLR in THP-1 macrophages

Progress in Biochemistry and Biophysics

Volumn 35, Issue 5, 2008, Pages 540-547

  Liu, Lu Shan ^a   Cheng, Yan Li ^a   Xie, Min ^a   Yang, Qiong ^a   Pan, Li Hong ^a   Jiang, Zhi Sheng ^a   Tang, Chao Ke ^a   Wei, Dang Heng ^a   Tang, Zhi Han ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Atherosclerosis; LDL; LDLR; oxLDL; PCSK9 NARC 1; THP 1 macrophage

Indexed keywords

EID: 48249111837     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Cheng Y L, Xie M, Liu L S, et al. Chin J Biolchem Mol Biol, 2007, 23(3): 172-176
2. Yang Y Z. Basic and Clinical Research on Atherosclerotic Cardiovascular Diseases. Beijing: Science Press, 2004. 11-14
3. Brown M S, Goldstein J L. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986, 232(4746): 34-47
4. Parthasarathy S, Printz D J, Boyd D, et al. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Atherosclerosis, 1986, 6(5): 505-510
5. Manurung D. Lipid profiles of acute coronary syndrome patients hospitalized in ICCU of Cipto Mangunkusumo Hospital. Acta Med Indones, 2006, 38(4): 196-201
6. Maxwell K N, Breslow J L. Adenoviral-mediated expression of PCSK9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA, 2004, 101(18): 7100-7105
7. Maxwell K N, Fisher E A, Breslow J L, et al. Over expression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA, 2005, 102 (6): 2069-2074
8. Jirholt P, Adiels M, Bore'n J. How does mutant proprotein convertase neural apoptosis-regulated convertase 1 induce autosomal dominant hypercholesterolemia?. Arterioscler Thromb Vasc Biol, 2004, 24(8): 1334-1336
9. Shioji K, Mannami T, Kokubo Y, et al. Genetic variants in PCSK9 affect the cholesterol level in Japanese. J Hum Genet, 2004, 49(2): 109-114
10. Naoumova R P, Tosi I, Patel D, et al. Severe hypercholesterolemia in four british families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol, 2005, 25(12): 2654-2660
11. Damgaard D, Jensen J M, Larsen M L, et al. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes. Atherosclerosis, 2004, 177(2): 415-422
12. Brown M S, Goldstein J L. Lowing LDL-not only how low, but how long?. Science, 2006, 311:1721-1723
13. Park S W, Moon Y A, Horton J D, et al. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem, 2004, (79): 50630-50638
14. Rashid S, Curtis D E, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci USA, 2005, 102 (15): 5374-5379
15. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol, 2004, 24(8): 1454-1459
16. Thomas A L, David E C, Rita G, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Inves, 2006, 116(11): 2995-3005
17. Holla O L, Cameron J, Berge K E, et al. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol, 2007, 8: 9
18. Qian Y W, Schmidt R J, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res, 2007, 48(7): 1488-1498